MedTrace Logo

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

NCT05496465 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-04-07

Study results available
· View outcomes & findings →

Summary

Determine the effect of ARS-1 on a patient reported pruritus/hive score

Conditions

  • Urticaria

Interventions

DRUG

ARS-1

A single treatment of ARS-1 1mg, 2 mg or placebo

Sponsors & Collaborators

  • ARS Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Sarina Tanimoto, MD, PhD · ARS Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-28
Primary Completion
2024-02-29
Completion
2024-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05496465 on ClinicalTrials.gov